Japanese Site 1
Multiple Locations, Japan
Location status: Recruiting
NCT Number: NCT07746544
The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.
Interested in participating?
Request Info12 year–74 year
All sexes
Interventional
Phase 3
Multiple Locations, Japan
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Secutrelvir will be administered orally as a tablet.
Other names: S-892216
Placebo will be administered orally as a tablet.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline, Day 8
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary
Time frame: Baseline through Day 28
Time frame: Baseline through Day 21
Time frame: Baseline through Day 21
Time frame: Days 4 and 8
Time frame: Baseline through Day 28
Contact information is provided by the study sponsor or research team.
Shionogi Clinical Trials Administrator Clinical Support Help Line
CONTACT
Shionogi
Industry
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07536308
COVID-19, Coronaviridae Infections
Decatur, Georgia, United States
View Trial DetailsNCT01306084
Adenoviridae Infections, Anogenital Herpes
Bethesda, Maryland, United States
View Trial DetailsNCT06417762
Behavior, COVID-19
Chicago, Illinois, United States
View Trial DetailsNCT06810934
COVID-19, Coronaviridae Infections
Los Angeles, California, United States
View Trial Details